Michael Merker

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Pediatric intensive care follow-up in Germany is rarely established and highly heterogeneous: a nationwide survey of 20 PICUs.

Pediatric intensive care follow-up in Germany is rarely established and highly heterogeneous: a nationwide survey of 20 PICUs.

Journal: Molecular and cellular pediatrics

Published: June 11, 2026

External validation of the VALE scoring system for hemorrhage risk in pediatric AVM patients.

External validation of the VALE scoring system for hemorrhage risk in pediatric AVM patients.

Journal: Neurosurgical review

Published: January 01, 2026

Pediatric Intensive Care Core Outcomes-a modified Delphi consensus process (PIC-CO).

Pediatric Intensive Care Core Outcomes-a modified Delphi consensus process (PIC-CO).

Journal: Critical care (London, England)

Published: December 01, 2025

Didactic and Content Quality of Basic Life Support Videos on YouTube: Cross-Sectional Study.

Didactic and Content Quality of Basic Life Support Videos on YouTube: Cross-Sectional Study.

Journal: JMIR formative research

Published: November 28, 2024

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

Journal: Frontiers in immunology

Published: August 24, 2024

Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany.

Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany.

Journal: CNS drugs

Published: October 25, 2023

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.

Journal: Molecular therapy. Oncology

Published: August 18, 2023

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.

Journal: Frontiers in immunology

Published: May 25, 2023

Pediatric ICU Admissions After Adolescent Suicide Attempts During the Pandemic.

Pediatric ICU Admissions After Adolescent Suicide Attempts During the Pandemic.

Journal: Pediatrics

Published: May 04, 2022

Impact of the First COVID Lockdown on Accident- and Injury-Related Pediatric Intensive Care Admissions in Germany-A Multicenter Study.

Impact of the First COVID Lockdown on Accident- and Injury-Related Pediatric Intensive Care Admissions in Germany-A Multicenter Study.

Journal: Children (Basel, Switzerland)

Published: January 27, 2022

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.

Journal: Cancers

Published: February 23, 2021

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Journal: Frontiers in immunology

Published: July 08, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026